Polarean Imaging PLC - Collaboration to Advance Lung Imaging Innovation
Polarean and SimonMed Announce Collaboration to Advance Lung Imaging Innovation
Polarean Imaging plc (AIM: POLX) has partnered with SimonMed Imaging to integrate its Xenon MRI platform across SimonMed's extensive U.S. network. This collaboration aims to enhance functional lung imaging capabilities, starting with Scottsdale, Arizona.
Prospex Energy PLC - Approval of 3D Seismic Campaign
Italy - Selva Malvezzi Production Concession
Prospex Energy plc announces that Po Valley Energy Limited has secured regional approval to commence a 3D seismic campaign in the Selva Malvezzi Production Concession Area, Italy. The seismic data will guide the drilling of four new wells to enhance gas extraction and further development, aiming for optimal resource targeting.
Audioboom Group PLC - Creator Network Growth and Expansion of Sales Team
UK Creator Network Growth and Expansion of UK Sales Team
Audioboom Group plc (AIM: BOOM), a global podcast leader, announces expanded UK creator partnerships, including "No Such Thing As A Fish" and collaborations with Hat Trick Productions and Filthy @ Five. Additionally, Liv Suco joins as Senior Account Director to strengthen the UK sales team, enhancing the company's market presence and monetisation capabilities.
Great Western Mining - Western Milling Update
Western Milling Update
Great Western Mining Corporation has completed the Nevada state inspection of its Western Milling project. Minor upgrades are needed before production can begin. Environmental checks are finalized, and no significant issues have been found. Production is set to commence once minor health and safety improvements are addressed by the operating partner.
Nuformix PLC - NXP002 ODD Application Submitted
NXP002 Orphan Drug Designation Application Submitted
Nuformix plc has applied to the European Medicines Agency for Orphan Drug Designation for NXP002, a potential inhaled treatment for Idiopathic Pulmonary Fibrosis. The application includes coordination by EMA members and is expected to yield an opinion by day 90. Nuformix is also exploring potential partnerships for NXP002 licensing opportunities.